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Background: Cytoreductive surgery (CS) followed by heated intraperitoneal chemotherapy
(HIPEC) is considered the standard of care for the treatment of patients with peritoneal
carcinomatosis (PC) of colorectal cancer (CRC). These surgical procedures result in a median
survival of 2 years at the cost of considerable morbidity and mortality. In preclinical studies,
radioimmunotherapy (RIT) improved survival after CS in a model of induced PC of colonic
origin.
In the present studies we aimed to compare the efﬁcacy and toxicity of CS followed by
adjuvant RIT in experimental PC to the standard of care, HIPEC.
Methods: PC was induced by intraperitoneal inoculation of CC-531 colon carcinoma cells
in three groups of Wag/Rij rats. Treatment comprised CS only, CS + RIT or CS + HIPEC,
immediately after surgery. RIT consisted of intraperitoneal administration of 74 MBq Lute-
tium-177 labeled MG1. HIPEC was performed by a closed abdomen perfusion technique
using mitomycin C (16 mg/L during 60 minutes). The primary endpoint was survival.
Results: CS only or combined with RIT was well tolerated. Rats receiving CS + HIPEC
were lethargic, suffered from diarrhea, and lost signiﬁcantly more weight in the ﬁrst postop-
erative week. Median survival of rats treated with CS + RIT was signiﬁcantly longer than
after CS alone (97 and 57 days, respectively, P < .004), whereas survival after CS + HIPEC
or CS alone were not signiﬁcantly different (76 and 57 days, respectively, P = .17).
Conclusion: Survival after CS was signiﬁcantly improved by RIT with Lutetium-177-MG1
in rats with PC of colorectal origin. Adjuvant HIPEC did not improve survival and was more
toxic than adjuvant RIT.
Key Words: Radioimmunotherapy—Cytoreductive surgery—Heated intraperitoneal chemo-
therapy—Peritoneal carcinomatosis—Colon cancer—Adjuvant.
Peritoneal carcinomatosis (PC) of colorectal cancer
(CRC) frequently is an end stage of colorectal cancer,
occurring in 5–50% of the patients, either synchro-
nous or metachronous.
1 If untreated, patients suf-
fering from PC have a median survival of only 6
months.
2 Survival is signiﬁcantly improved by radical
surgical debulking procedures (cytoreduction) in
combination with intraperitoneal chemotherapy, ei-
ther in combination with normothermia or hyper-
thermia (HIPEC).
3–7 The median survival after
cytoreductive surgery and HIPEC is 13–34 months,
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3274and the 5-year survival rate is 19–27% at the cost of
considerable morbidity and mortality rates of up to
23% and 4%, respectively.
6,9
In the latest reported clinical trial on adjuvant RIT
in the setting of colon cancer, Liersch et al. reported
results of a Phase II trial with
131I-labeled anti-CEA
antibody labetuzumab administered to patients after
complete resection of colorectal liver metastases. This
study, where RIT was applied in an adjuvant setting
to complete resection, resulted in a promising 5-year
survival rate of 51.5%.
10 Radioimmunotherapy using
radiolabeled monoclonal antibodies directed against
tumor-associated antigens may therefore be an
attractive anticancer therapy in patients with small
volume disease.
We therefore have studied the application of RIT as
adjuvant therapy following cytoreductive surgery
(CS) in the setting of PC. In previous studies regarding
PC of CRC in a rat model we showed that RIT could
be an eﬀective adjuvant treatment after CS. The eﬃ-
cacy of adjuvant RIT in combination with CS was
investigated and compared with no treatment, CS
only, and RIT only. The results of this study showed a
signiﬁcantlyimprovedsurvivalofanimalstreatedwith
CS followed by RIT (median 88 days) compared with
those treated with CS only (median 51 days) and RIT
only (median 61.1 days).
11 Based on the encouraging
results, showing the observed increase in survival that
was achieved with low-dose RIT and concomitant low
toxicity, we now aimed to compare the efﬁcacy of this
treatment to that of todays standard of care, HI-
PEC,
12,13 in a preclinical setting.
MATERIALS AND METHODS
Animal Model of Peritoneal Carcinomatosis
WAG/Rij rats (10–12 weeks old, body weight 240–
290 g, Harlan Horst, The Netherlands) were housed
under nonsterile standard conditions (temperature,
20–24 C; relative humidity, 50–60%; 12-h light/dark
cycle) in filter-topped cages (two rats per cage), with
free access to food (Ssniff, Bio Services Uden, The
Netherlands) and water. Rats were accustomed to
laboratory conditions for at least 1 week before
experimental use. Peritoneal carcinomatosis was in-
duced by intraperitoneal inoculation of 2.0 · 10
6 CC-
531 colon cancer cells, as described previously.
14 All
experiments were approved by the local Animal
Welfare Committee of the Radboud University Ni-
jmegen and were carried out in accordance with the
Dutch Animal Welfare Act of 1997.
Operative Procedure
Prior to the laparotomy, all rats were given 10 mL
of saline to prevent hypovolemia. Surgical procedures
were performed under general anaesthesia using iso-
ﬂurane 3%,O 2 and N2O 1:1. Thirty minutes prior to
and once daily until the third day postoperatively,
rats were given buprenorphine (5 lg, 0.1 mL/rat/day)
for analgesia. During the operation, rats were placed
on a warmed mattress to limit body heat loss. All rats
underwent a midline laparotomy. After opening the
abdomen the extent of intraperitoneal tumor growth
was scored semiquantitatively, 0 (no macroscopic
tumor), 1 (little; located at 1–2 sites with a diameter
of 1–2 mm), 2 (moderate; located at 1–2 sites and a
diameter 2–5 mm), or 3 (abundant; located at mul-
tiple sites and/or diameter >5 mm) in all four
quadrants of the abdomen. The sum of the tumor
scores of all sites represented the peritoneal cancer
index (PCI).
11
Subsequently, CS, including a routine omentec-
tomy, was performed in all rats. Irresectable tumor
deposits were cauterized using an electrocoagulation
device. After completion of the surgical cytoreduc-
tion, the abdominal wall was closed in two layers
using continuous Vicryl 3/0 sutures for the muscular
component and iron wound clips for the skin in
animal treated with CS only or CS + RIT.
Monoclonal Antibody, Radiolabeling, and RIT
The murine MG1 monocolonal antibody (MAb),
an anti-CC531 IgG2a monoclonal antibody that
recognizes a 80 kDa cell surface antigen and localizes
preferentially in tumors when injected in rats bearing
CC-531 tumors,
15 was purchased from Antibodies for
Research Applications BV (Gouda, The Nether-
lands). Labeling of the antibody with
177Lu was
carried out as previously described.
11 In brief, the
MAb was conjugated with 2-(4-isothiocyanatoben-
zyl)-diethylenetriaminepenta-acetic acid (ITC-
DTPA) (Macrocyclics, Dallas, TX) and subsequently
labeled with
177Lutetium (IDB Holland, Baarle
Nassau The Netherlands) and puriﬁed by gel ﬁltra-
tion on a PD10 column (Amersham, Pharmacia
Biotech, Maarsen, The Netherlands). The puriﬁed
177Lu-MG1 preparation was diluted in PBS with
0.5% BSA for injection, the speciﬁc activity of the
administered
177Lu-MG1 preparation was 0.4 MBq/
lg. The labeling procedure using
177Lu was per-
formed under strict metal-free conditions.
RIT (185 lg MG1/ rat, radiolabeled with 74 MBq
177Lu in 3.0 mL) was intraperitoneally injected
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the most optimal time for adjuvant administration.
16
Mitomycin-C
Mitomycin-C (MMC) was obtained from Ny-
comed Christiaens BV (Breda, The Netherlands) as a
powder in glass vial (40 mg/vial). Immediately before
use, MMC was dissolved in 0.9% sodium chloride to
the appropriate concentrations.
HIPEC Procedure
Following CS, while the abdomen was still ex-
posed, two multiperforated catheters (Argyle, Sher-
wood Medical, Ireland) were inserted laterally
through the abdominal wall and subsequently ﬁxed in
the abdominal cavity. The inﬂow drain was placed in
the right paracolic gutter, the outﬂow drain in the left
subdiaphragmatic space. The intraperitoneal tem-
perature was monitored with an intra-abdominal
thermometer (PTFE Insulated thermocouple, VWR
International, Amsterdam, The Netherlands), at the
site with generally the highest tumor load (omentum).
In addition, a thermometer was placed inside the
rectum. After placement of the catheters, the
abdominal wall was closed using a continuous suture
(Ethilon 3.0, Johnson & Johnson, Ethicon) (Fig. 1).
During the HIPEC procedure, rats were removed
from the warmed mattress to prevent general hyper-
thermia. The perfusion system was ﬁlled with 250 mL
saline, containing 4 mg MMC (Mitomycin-C Kyowa,
Christiaens). The perfusate was heated in a tube coil
using a thermostatically regulated water bath set to a
temperature of 48 C and infused into the peritoneal
cavity by a roller pump (Ismatec IPS-8, Ismatec SA,
Glattbrugg, Switzerland) for the duration of 60
minutes at 10 mL/min. Abdominal inﬂow tempera-
ture was set at 44 C. In order to achieve a uniform
heat distribution, gentle massage of the abdomen was
applied throughout the duration of the HIPEC pro-
cedure. After completion of the perfusion, the
abdominal cavity was ﬂushed with warmed (37 C)
saline for a period of 10 minutes. The abdomen was
opened again to remove the catheters. Subsequently,
the abdomen was closed as described previously.
Intraperitoneal Distribution of MMC and Dose
Determination
Prior to the therapy experiment with HIPEC, we
investigated the intraperitoneal distribution of the
perfusion ﬂuid using a methylene blue stained per-
fusate. The perfusate was administered in the same
fashion as in the therapeutic experiment. After com-
pletion, the abdominal cavity was inspected for the
presence of blue dye in all quadrants on both parietal
as well as visceral peritoneum of the intra-abdominal
organs and the diaphragm. Subsequently, a study to
determine the dose of MMC that resulted in accept-
able toxicity was performed in nine animals (three
animals per group). Animals underwent a laparot-
omy including an omentectomy and complete bowel
inspection followed by heated perfusion of the
abdominal cavity with MMC at 4 mg/L or 16 mg/L.
Control rats underwent laparotomy and an omen-
tectomy only. Body weight and physical condition
were monitored during 6 days following the proce-
dure to assess treatment-related toxicity.
Treatment Efﬁcacy
Seven days after intraperitoneal tumor induction
with 2.0 · 10
6 CC-531 tumor cells, 45 rats, 15 per
treatment group, were randomly assigned to undergo
either CS only, CS + RIT or CS + HIPEC. The
operative procedures and application of the adjuvant
therapies were performed as described previously.
Toxicity of the treatment was determined clinically
and by weighing the rats. Body weight was expressed
as relative body weight compared with the body
weight on the day of surgery. Survival was scored,
and at autopsy the extent of tumor growth was
determined.
Follow-Up
The primary endpoint was 16-week survival. As
part of monitoring the physical condition during the
FIG. 1. HIPEC Perfusion System; MMC Mitomycin C Kyowa 16
mg/L perfusate. Adapted from Ref. 19. Reproduced with permis-
sion.
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tion was monitored and the body weight was mea-
sured daily during the ﬁrst 2 weeks. When the
humane endpoint (HEP) was reached (signs of mas-
sive hemorrhagic ascites, physical inactivity or signs
of intra-abdominal tumor growth with invalidating
consequences), rats were killed by O2/CO2-adminis-
tration and immediately dissected. The HEP was
determined by an experienced biotechnician who was
blinded to the therapeutic regimen. At the time of the
HEP rats were generally lethargic, showing signs of
advanced PC as the presence of ascites. At dissection,
the intraperitoneal tumor growth was scored as de-
scribed previously. At 16 weeks postoperatively, the
study was terminated and the remaining rats were
euthanized and dissected. In case of absence of
macroscopic tumor, all relevant organs, including the
greater momentum, the mesentery, and the dia-
phragm were removed for histopathological staining
to determine tumor presence microscopically. Sec-
tions were stained using hematoxylin & eosin (H&E)
and/or immunohistochemical staining using the
murine MG1 antibody in combination with a horse-
anti-mouse IgG antibody, HRP conjugated (Vector
Laboratories Inc., Burlingame, CA, USA).
Statistical Analysis
Statistical analysis was performed using SPSS
(Chicago, IL) software and Graphpad Prism (Graph-
pad Software Inc., San Diego CA) for analysis. Com-
parison of dichotomous values was done using chi-
square or Fishers Exact test. Nonparametric testing
was performed using two-way ANOVA testing. Sur-
vivalcurveswereanalyzedusingKaplan–Meiercurves
and compared by means of the log-rank test. Post-
testing using Bonferroni was applied to correct for
multiple groups. All tests were two-sided; the level of
statistical significance was set at a P value of <.05.
RESULTS
Intraperitoneal Distribution of HIPEC and Dose
Determination
The intraperitoneal distribution of the perfusate
administered according to the previously described
procedure, showed a distribution pattern amongst all
quadrants, including the diaphragm bilaterally and at
the mesenterial root (Fig. 2).
The applied dose of 16 mg MMC/L resulted in a
maximum mean weight loss of 13.7 ± 2.9% at 4
days postoperatively. In addition, the ﬁrst 3 days
following the heated perfusion, animals were
lethargic and suﬀered from diarrhea from day 2
until day 4 postoperatively. In contrast, the maxi-
mum weight loss in the 4 mg/L was 8.3 ± 2.9% at
day 3 and 7.5 ± 2.3% at day 3 in the control group
(Fig. 3). None of the animals died during the
immediate postoperative period. Based on these
observations, HIPEC, when administered at a dose
of 16 mg/L for the duration of 60 minutes at the
given temperature, was considered to be the
maximal tolerable dose to be used for the HIPEC
procedure.
FIG. 2. Intraperitoneal distribution of methylene blue stained
perfusate.
FIG. 3. The relative body weight of Wag/Rij rats after exploratory
laparotomy (control) and heated intraperitoneal chemotherapy
(HIPEC) given immediately postoperatively in different doses.
Data represent means ± standard error of the mean (SEM).
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Preoperative body weight did not diﬀer between
groups, P = .52 (Table 1) At laparotomy, tumor
nodules were present in the omentum, liver hilum, the
mesentery, and gonadal fatpads (1–3 mm diameter).
Median PCI score at time of surgery was 5 (range 4–
8) and was similar in all experimental groups. After
surgical cytoreduction, residual disease remained
in situ in 7 rats after cauterization and was equally
distributed among the groups (P = .84). The surgical
procedures without adjuvant therapy took 20–30
minutes per animal.
There was no intraoperative mortality. However,
one rat in the CS + HIPEC and one rat in the CS +
RIT group were euthanized after 2 and 9 days,
respectively. The animal in the CS + HIPEC group
showed massive weight loss as a result of bowel
necrosis and subsequent perforation, the cause of
death of the animal in the CS + RIT group remained
unclear. The median intra-abdominal temperature
during the HIPEC procedure, measured at the site
where the greater omentum was removed, was 41.0 C
(range 40.4–41.6 C). In contrast, the median rectal
temperature was 34.6 C (range 34.1–34.8 C) (Fig. 4).
CS and CS + RIT were well tolerated, whereas
animals in the CS + HIPEC groups showed signs of
physical discomfort; animals of the latter group were
generally lethargic and showed pilo erection two days
following the procedure. In addition, these animals
all suﬀered from diarrhea up to 4 days after the HI-
PEC procedure. The relative body weight after of
the various treatment groups is depicted in Fig. 5.
Maximum body weight loss after CS or CS + RIT
was similar (7.3 ± 2.6% vs 9.3 ± 1.8% 4 days post-
operatively, P > .05). Rats that received adjuvant
HIPEC had a maximum body weight loss of
12.3 ± 1.7%, which was signiﬁcantly higher than
that after CS alone (P < .001) or CS + RIT (P <
.001). Rats generally gained weight from the ﬁfth
postoperative day onward. In the HIPEC group,
however, postoperative mean body weight remained
signiﬁcantly lower than that of the animals in the CS
group, until 5 weeks postoperatively.
Treatment Efﬁcacy
During the experiment, 29 animals were euthanized
because of massive amounts of ascites that resulted
from intraperitoneal tumor growth. The mean
TABLE 1. Treatment group characteristics
PCI
Median (range)
CS CS + HIPEC CS + RIT
Preoperative body weight (g) 266 (251–287) 264 (245–285) 262 (244–276)
Tumor score per site
Greater omentum 2 (2–3) 2 (1–2) 2 (1–2)
Liver hilum 1 (0–1) 1 (0–1) 1 (0–1)
Perisplenic 0 (0–1) 0 (0) 0 (0)
Mesentery 1 (0–2) 1 (0–2) 1 (0–2)
Gonadal fatpads 0 (0–2) 0 (0–2) 1 (0–2)
Diaphragm 0 (0–1) 0 (1) 0 (0–1)
Parietal peritoneum 1 (0–1) 1 (0–1) 1 (0–1)
Total 5 (4–8) 5 (4–6) 5 (4–8)
Resection macroscopically complete
Yes 12 13 13
No 3 2 2
Treatment group characteristics (peritoneal cancer index; PCI) found during laparotomy before the administration of the adjuvant therapy.
CS, cytoreductive surgery; HIPEC, heated intraperitoneal chemotherapy; RIT, radioimmunotherapy. PCI is expressed as median and range.
FIG. 4. The recorded intra-abdominal and rectal temperature
during the HIPEC procedure. Data represent means ± standard
error of the mean (SEM).
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31 ± 22.6 mL, 26.5 ± 23.8 mL, and 26.4 ± 22.6
mL in the CS, RIT, and HIPEC groups, respectively
(P = .82). At the time of death, mean PCI in the CS,
CS + HIPEC, and CS + RIT groups was 18 (range
9–22), 12 (range 5–15), and 18 (range 16–19),
respectively, with significant differences between the
CS + HIPEC and both other treatment groups (P <
.001 for both comparisons).
The survival curves of the various treatment
groups are depicted in Fig. 6. Median survival of the
rats that were treated with CS only was 57 days
(range 36–112). Adjuvant HIPEC resulted in a med-
ian survival of 76 days (range 33–112), P = .17, when
compared with CS only. Median survival of the rats
that were treated with CS followed by the adjuvant
administration of RIT was improved to a median
survival of 97 days (range 49–112), P < .001 com-
pared with CS only. When compared with CS fol-
lowed by adjuvant HIPEC, the adjuvant
administration of RIT to surgery did not result in an
improved survival (P = .33).
At the endpoint of the study, 16 weeks after CS, 14
animals (two animals in the CS group, ﬁve animals in
the CS + HIPEC group, and seven animals in the CS
+ RIT group) were still alive, without any physical
signs of intraperitoneal tumor growth.
Of these 14 animals that were still alive 16 weeks
after surgery, one animal in the CS + HIPEC group
and three animals in the CS + RIT group showed
macroscopic evidence of tumor at dissection. In the
remaining 10 animals (two in the CS alone group,
four in the HIPEC group, and four in the RIT group)
not even microscopic tumor presence was found.
DISCUSSION
In the present study, adjuvant radioimmunothera-
py after cytoreductive surgery for peritoneal carci-
nomatosis of colorectal origin in rats signiﬁcantly
improved survival, whereas HIPEC did not. In
addition, the application of HIPEC was associated
with considerably more toxicity as compared to RIT.
The treatment of peritoneal carcinomatosis was
studied with CC-531 syngeneic tumors that grew
intraperitoneally in Wag/Rij rats. This model is
highly reproducible, and the growth and distribution
pattern throughout the abdominal cavity are similar
to the human entity of PC.
14 Cytoreduction per-
formed at 7 days after tumor reduction resulted in
minimal residual disease (<1 mm). In this setting,
both HIPEC and RIT result in maximum therapeutic
efﬁcacy.
12,13,17
The MG1 MAb preferentially localizes in the CC-
531 tumors,
11 with only minor localization in thymus,
lymph node, salivary gland tissue, and skin.
15 177Lu
was selected as the radionuclide for RIT of minimal
residual disease because of its high tumor uptake and
adequate physical properties including a medium-en-
ergy b-emission with a maximum penetration range in
tissue of 2.5 mm. In our previous studies we have used
the combination of
177Lu-MG1 radionuclide-anti-
body. These studies demonstrated the combination to
be highly effective for the improvement of survival in
the model of PC as described previously.
11,16 More-
over, in previous experiments we have shown that
FIG. 6. Kaplan–Meier survival curves for Wag/Rij rats with small
peritoneal CC-531 tumors after cytoreductive surgery (CS), CS +
RIT (RIT) or CS + HIPEC (HIPEC).
FIG. 5. The relative body weight of Wag/Rij rats with small
peritoneal CC-531 tumors in the ﬁrst 14 days after cytoreductive
surgery (CS) only, CS + radioimmunotherapy given immediately
postoperatively (RIT) or heated intraperitoneal chemotherapy
(HIPEC) given immediately postoperatively. Data represent
means ± standard error of the mean (SEM).
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antibody is less effective by far compared with therapy
with a radiolabeled speciﬁc antibody.
18 HIPEC has
been studied in only a few preclinical studies.
19–22
These studies showed that its use was associated with
a decreased tumor load compared with control
groups.
19 However, in these studies, HIPEC was
associated with a considerable toxicity, indicated by
lethargy, marked body weight loss, and bacterial
translocation.
23 These results on toxicity are in cor-
roboration with the results of our study and mimic the
clinical effects of HIPEC. Clinical studies with post-
operative intraperitoneal chemotherapy are associ-
ated with a high mortality and morbidity.
12
Of 16 published reports on the use of HIPEC in the
clinical setting, 13 reports described the administra-
tion of MMC.
12 In vitro, MMC has also shown to
inhibit growth of CC531 cells in a concentration a
thousand-fold lower than the concentration used in
the present experiment.
24 The applied dose of 16 mg/
L MMC in our study is within the range of doses
applied in clinical practice (5–20 mg/L
25) and is
higher than described in other preclinical studies
(2.25 mg/L
19 and 4 mg/L
22). In addition, in the
present study HIPEC was applied as an adjuvant
treatment to cytoreduction, whereas Pelz et al.
19 ap-
plied HIPEC as monotherapy with subsequent killing
of the animals after only 10 days.
The intraperitoneal distribution of MMC during
the perfusion was studied before the start of the actual
experiment and showed equal distribution among all
quadrants. The eﬀect of the perfusion technique on
distribution diﬀerences and their associated diﬀer-
ences in survival have never been studied clinically.
Glehenandcolleaguesperformedalargeclinicalstudy
in 506 patients that were treated with both the open
and closed abdomen perfusion technique. The authors
reported no diﬀerences in survival between both per-
fusiontechniques.
6Thisobservationwasconﬁrmedby
the study of Sugarbaker and colleagues.
26
RIT with 74 MBq of the
177Lu-MG1 radionuclide-
antibody in 3 mL has previously been shown to be an
effective treatment for experimentally induced PC of
colonic origin when administered intraperitone-
ally.
11,16 The biodistribution of intraperitoneally in-
jected
111In-labeled MG1 was studied by Koppe et al.
and showed a preferential uptake of the radiolabeled
antibody in the tumor.
11
The extraperitoneal temperature of 48 C necessary
to obtain inﬂow temperatures of 44 C would not
have had a negative inﬂuence on the cytotoxicity of
MMC, since Ahrar et al.
27 showed that only tem-
peratures exceeding 60 C decreased its cytotoxic ef-
fect. On the other hand, one has to bear in mind the
fact that the additive effect of hyperthermia in HI-
PEC in the clinical setting has not yet been proven in
a randomized trial. Elias et al. and Glehen et al. both
reported the use of early postoperative chemotherapy
(EPIC), without hyperthermia, ranging from day 1 to
day 5 after surgery, and HIPEC. Elias et al. found no
signiﬁcant difference in survival. Similarly, in the
multicenter study in 506 patients of whom 53.3 and
24.3 % underwent HIPEC and EPIC alone, no sig-
niﬁcant difference was found in survival between the
two treatment groups.
6 The duration of the heated
perfusion, 60 min. in this experiment, is in concor-
dance with the recent consensus statement regarding
Cytoreductive Surgery and Hyperthermic Intraperi-
toneal Chemotherapy in the Management of Perito-
neal Surface Malignancies of Colonic Origin, stating
that the perfusion should last 60–120 minutes.
13
These data on the dose of MMC, the used perfusion
time and temperature, together with our results that
showed antitumor effect in the model of induced PC
from CC531 cells (signiﬁcantly lower PCI at HEP in
favor of CS + HIPEC), we can conclude that the
HIPEC model used in our study was able to induce
regression of PC of colonic origin.
In the latest reported clinical trial on adjuvant RIT
in the setting of colon cancer, Liersch et al. reported
results of a Phase II trial with
131I-labeled anti-CEA
antibody labetuzumab administered to patients after
complete resection of colorectal liver metastases. This
study, where RIT was applied in an adjuvant setting
to complete resection, resulted in a promising 5-year
survival rate of 51.5%.
10 The results of this study is in
accordance with the conclusion of a recent review on
the use of RIT to treat colon cancer.
17 In this review,
the authors state that the time may have come for
clinical trials in which RIT is added to standard
regimens to establish the place of this treatment
modality as an adjuvant treatment after CS.
To our knowledge, the present study is the ﬁrst
study comparing the use of RIT and HIPEC in an
adjuvant setting to CS for the treatment of PC in
colorectal cancer. Our preclinical studies indicate that
the application of RIT immediately following CS can
improve survival in rats with PC of CRC. Moreover,
from the present study we conclude that the use of
adjuvant RIT is an eﬀective treatment with low tox-
icity. When compared with todays standard of care,
HIPEC, RIT was at least as eﬀective. RIT consisted
of an activity dose of 74 MBq of
177Lu-labeled
MG1per rat, resulting in only minor toxicity, whereas
the theoretical MTD of
177Lu-labeled antibodies in
250 g rats could be approximately 150 MBq.
11
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applications of adjuvant RIT. For example, after
cytoreductive surgery, patients are transferred to the
intensive care unit. Optimal patient care has to be
balanced with radiation safety issues for the medical
staﬀ. Previously, we reported on the optimal time
interval between RIT and CS.
16 In that study, we
showed that RIT should be administered as soon as
possible after CS, with a window of opportunity for
RIT administration up to 4 days after surgery. It can
therefore be envisioned that for radiation safety rea-
sons the therapy should be given not before discharge
of the patient from ICU and removal of the
abdominal drains.
Our study therefore justiﬁes the consideration of
intraperitoneal radioimmunotherapy after cytore-
ductive surgery in case of peritoneal carcinomatosis
of colorectal cancer. In clinical studies, this approach
should be compared with HIPEC.
CONCLUSION
This study showed that RIT adjuvant to CS sig-
niﬁcantly improved survival compared to CS alone in
a rat model of PC of CRC, whereas the contempo-
rary gold standard, HIPEC, did not cause a signiﬁ-
cant improvement in survival. This improvement of
survival was associated with a decreased level of
treatment-related toxicity compared with HIPEC.
Adjuvant radioimmunotherapy might therefore be an
alternative adjuvant treatment after cytoreductive
surgery of PC of colorectal origin in a clinical trial
setting.
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